½ÃÀ庸°í¼­
»óǰÄÚµå
1577007

Àڱà ³» ÇÇÀӱⱸ ½ÃÀå, ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)

Intrauterine Devices Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 160 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

2023³â 43¾ï ´Þ·¯¿´´ø ¼¼°è Àڱà ³» ÇÇÀӱⱸ ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö 10.3%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 101¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°èȹµÇÁö ¾ÊÀº ÀÓ½ÅÀ¸·Î ÀÎÇØ È¿°úÀûÀÎ ÇÇÀÓÀÇ Çʿ伺ÀÌ ºÎ°¢µÇ¸é¼­, ´õ ¸¹Àº »ç¶÷µéÀÌ ½Å·ÚÇÒ ¼ö ÀÖ´Â Àå±âÀûÀÎ ¿¹¹æÀ» À§ÇØ IUD·Î ´«À» µ¹¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡Á·°èȹ ¹× »ý½Äº¸°ÇÀ» Àå·ÁÇÏ´Â Á¤ºÎ ÇÁ·Î±×·¥Àº IUDÀÇ Á¢±Ù¼º°ú ÀÎÁöµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÇÕÀûÀÎ ¿äÀεéÀÌ IUDÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í ½ÃÀå È®´ë¿¡ ±â¿©ÇÏ¿© È¿°úÀûÀÎ ÇÇÀÓ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àڱà ³» ÇÇÀӱⱸ »ê¾÷Àº Á¦Ç°, ¿¬·É´ë, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

È£¸£¸ó IUD ºÐ¾ß´Â 2023³â È£¸£¸ó IUDÀÇ È¿°ú¿Í ±âÁ¸ ¹æ½Ä¿¡ ´ëÇÑ ´Ù¸¥ ÀåÁ¡À¸·Î ÀÎÇØ 23¾ï ´Þ·¯ ½ÃÀå ±Ô¸ð¸¦ È®º¸Çß½À´Ï´Ù. È£¸£¸ó IUD´Â Àå±âÀûÀÎ ÇÇÀÓ È¿°ú¸¦ Á¦°øÇÏ´Â µ¿½Ã¿¡ ¿ù°æ ÃâÇ÷ °¨¼Ò, »ý¸®Åë ¿ÏÈ­ µîÀÇ ÀÌÁ¡ÀÌ ÀÖ¾î »ç¿ëÀڵ鿡°Ô ¸Å¿ì ¸Å·ÂÀûÀÔ´Ï´Ù. È£¸£¸ó IUDÀÇ ±â¼ú ¹ßÀü°ú ÀÌ·¯ÇÑ ÀåÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ±× ÀαⰡ ´õ¿í ³ô¾ÆÁ³½À´Ï´Ù. º¸´Ù È¿°úÀûÀÌ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ ÇÇÀÓ ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó È£¸£¸ó IUD°¡ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

º´¿ø ºÎ¹®Àº 2023³â 46.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Àü¹® ÀÇ·á ¼­ºñ½º¿Í Á¾ÇÕÀûÀÎ »ý½Ä ÀÇ·á¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. º´¿øÀº IUD »ðÀÔ ¹× °ü¸®¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Àü¹® ¼­ºñ½º¸¦ Á¦°øÇÏ¿© ½Å·ÚÇÒ ¼ö ÀÖ°í Àü¹®ÀûÀÎ ÇÇÀÓ ¼Ö·ç¼ÇÀ» ã´Â ȯÀÚµéÀ» ²ø¾îµéÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿øÀº °íµµÀÇ Àåºñ¿Í ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡¸¦ °®Ãß°í ÀÖ¾î IUDÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á½Ã¼³ÀÌ °¡Á·°èȹ¿¡ ´ëÇÑ ¿ì¼±¼øÀ§¸¦ °è¼Ó À¯ÁöÇÔ¿¡ µû¶ó º´¿ø ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÏ¹ÌÀÇ Àڱà ³» ÇÇÀӱⱸ ½ÃÀåÀº 2023³â 15¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó, »ý½Ä °Ç°­¿¡ ´ëÇÑ ³ôÀº ÀνÄ, Çö´ëÀû ÇÇÀÓ¹ý º¸±Þ¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á ¹× °¡Á·°èȹ ¼­ºñ½º¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, IUD¿¡ ´ëÇÑ Á¢±Ù¼º°ú ±³À°À» °­È­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥°ú ¿©¼º °Ç°­¿¡ ´ëÇÑ ³ôÀº °ü½ÉÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºÏ¹ÌÀÇ ÅºÅºÇÑ ÀÇ·á ½Ã½ºÅÛ°ú Àû±ØÀûÀÎ Á¢±Ù ¹æ½ÄÀº Àڱà ³» ÇÇÀӱⱸ »ê¾÷¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©£¦°úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±â¼ú Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • »óȯ ½Ã³ª¸®¿À
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • °¡°Ý ºÐ¼®
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç°º°, 2021³â-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ±¸¸® IUD
  • È£¸£¸ó IUD

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¿¬·ÉÃþº°, 2021³â-2032³â

  • ÁÖ¿ä µ¿Çâ
  • 15-19¼¼
  • 20-24¼¼
  • 25-29¼¼
  • 30-34¼¼
  • 35-39¼¼
  • 40-44¼¼
  • 45¼¼ ÀÌ»ó

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021³â-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ºÎÀΰú Ŭ¸®´Ð
  • Áö¿ª ÀÇ·á¼¾ÅÍ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021³â-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • Allergan(AbbVie Inc.)
  • Bayer AG
  • Contrel Europe
  • CooperSurgical Inc.
  • Durbin
  • EUROGINE, S.L
  • Gima S.p.A.
  • HLL Lifecare Limited
  • Meril Life Sciences Pvt. Ltd.
  • Mona Lisa N.V.
  • Mylan N.V.(Viatris)
  • OCON Medical Ltd.
  • Pregna International Ltd.
  • Prosan International BV
  • SMB Corporation of India
LSH 24.11.05

The Global Intrauterine Devices Market, worth USD 4.3 billion in 2023, will achieve USD 10.1 billion by 2032 at a 10.3% CAGR from 2024 to 2032, owing to the rising incidence of unplanned pregnancies and supportive government initiatives. As unplanned pregnancies highlight the need for effective contraception, more individuals are turning to IUDs for reliable, long-term prevention. Additionally, government programs promoting family planning and reproductive health enhance accessibility and awareness of IUDs. These combined factors are likely to boost the adoption of IUDs, contributing to the market's expansion and addressing the growing demand for effective contraceptive solutions.

The intrauterine devices industry is segregated on the basis of product, age group, end use , and region.

The hormonal IUD segment secured USD 2.3 billion in 2023 due to its effectiveness and additional benefits over traditional methods. Hormonal IUDs provide long-term contraception while also offering benefits like reduced menstrual bleeding and alleviation of menstrual cramps, making them highly appealing to users. Advances in hormonal IUD technology and increasing awareness of these benefits further drive their popularity. As demand for more effective and user-friendly contraceptive options grows, hormonal IUDs will lead the market.

The hospital segment held 46.8% share in 2023, driven by the high demand for professional medical services and comprehensive reproductive health care. Hospitals offer a range of specialized services, including the insertion and management of IUDs, attracting patients seeking reliable and expert contraceptive solutions. Additionally, hospitals are equipped with advanced facilities and trained healthcare professionals, enhancing the adoption of IUDs. As healthcare facilities continue to prioritize family planning, the hospital segment will dominate the market.

North America intrauterine devices market accumulated USD 1.5 billion in 2023, fueled by its advanced healthcare infrastructure, high awareness of reproductive health, and widespread adoption of modern contraceptive methods. The region benefits from significant investments in healthcare and family planning services, enhancing accessibility and education about IUDs. Additionally, favorable government policies and a strong focus on women's health further drive market growth. North America's robust healthcare system and proactive approach make it a key contributor to the intrauterine devices industry.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising awareness among women regarding various IUD applications
      • 3.2.1.2 High number of unintended pregnancies
      • 3.2.1.3 Government initiatives for the prevention of unwanted abortions and pregnancies
      • 3.2.1.4 Growing inclination towards planned delayed pregnancy
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of device
      • 3.2.2.2 Risk of several health issues
      • 3.2.2.3 Variability in insurance coverage and access
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
    • 3.6.3 Asia Pacific
  • 3.7 Reimbursement scenario
    • 3.7.1 North America
    • 3.7.2 Europe
    • 3.7.3 Asia Pacific
  • 3.8 Pricing analysis
  • 3.9 Gap analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Copper IUD
  • 5.3 Hormonal IUD

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 15-19
  • 6.3 20-24
  • 6.4 25-29
  • 6.5 30-34
  • 6.6 35-39
  • 6.7 40-44
  • 6.8 45+

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Gynecology clinics
  • 7.4 Community health care centers

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Allergan (AbbVie Inc.)
  • 9.2 Bayer AG
  • 9.3 Contrel Europe
  • 9.4 CooperSurgical Inc.
  • 9.5 Durbin
  • 9.6 EUROGINE, S.L
  • 9.7 Gima S.p.A.
  • 9.8 HLL Lifecare Limited
  • 9.9 Meril Life Sciences Pvt. Ltd.
  • 9.10 Mona Lisa N.V.
  • 9.11 Mylan N.V. (Viatris)
  • 9.12 OCON Medical Ltd.
  • 9.13 Pregna International Ltd.
  • 9.14 Prosan International BV
  • 9.15 SMB Corporation of India
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦